Amyloid-Beta Polyclonal Antibody

APP encodes a cell surface receptor and transmembrane precursor protein (amyloid beta precursor protein) that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for APP.

The Amyloid-beta Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of amyloid-beta protein in various biological samples. This antibody is produced through a rigorous process, ensuring its high affinity and specificity towards amyloid-beta.

With its exceptional performance, this antibody enables researchers to investigate the role of amyloid-beta in neurodegenerative diseases, such as Alzheimer's disease. It can be utilized in various applications, including Western blotting, immunohistochemistry, and ELISA, providing reliable and reproducible results.

The Amyloid-beta Polyclonal Antibody exhibits minimal cross-reactivity with other proteins, ensuring accurate and precise measurements. Its superior sensitivity allows for the detection of low levels of amyloid-beta, even in complex biological matrices.

This antibody is supplied in a convenient and ready-to-use format, ensuring ease of use and saving valuable time in the laboratory. It is available in different sizes to accommodate various experimental needs.

In summary, the Amyloid-beta Polyclonal Antibody is a valuable tool for researchers studying amyloid-beta protein and its implications in neurodegenerative diseases. Its high specificity, sensitivity, and ease of use make it an essential component in any research endeavor aiming to unravel the mysteries of amyloid-beta pathology.

The Amyloid-beta Polyclonal Antibody is a highly specific and sensitive tool designed for the detection and quantification of amyloid-beta protein in various biological samples. This antibody is produced by immunizing animals with a synthetic peptide corresponding to a specific region of the amyloid-beta protein sequence.

With its exceptional affinity and selectivity, this polyclonal antibody exhibits minimal cross-reactivity with other proteins, ensuring accurate and reliable results. It has been extensively validated for use in various applications, including Western blotting, immunohistochemistry, and enzyme-linked immunosorbent assays (ELISA).

The Amyloid-beta Polyclonal Antibody offers researchers a valuable tool for investigating the role of amyloid-beta in neurodegenerative diseases, particularly Alzheimer's disease. By targeting this specific protein, researchers can gain insights into the pathological mechanisms underlying these conditions and potentially develop novel therapeutic strategies.

This antibody is supplied as a liquid formulation, allowing for easy handling and storage. It is provided in various sizes to accommodate different experimental needs. Each batch of the Amyloid-beta Polyclonal Antibody undergoes rigorous quality control testing to ensure consistent performance and batch-to-batch reproducibility.

In summary, the Amyloid-beta Polyclonal Antibody is a reliable and versatile tool for the detection and quantification of amyloid-beta protein. Its high specificity, sensitivity, and validated performance make it an essential component in neurodegenerative disease research.